Loading stock data…
$1.50+0.03 (+2.05%)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.
Palisade Bio, Inc. in the Healthcare sector is trading at $1.50 with a market capitalization of $353M. Wall Street consensus targets $9.80 (10 analysts), implying a +555.5% move over the next 12 months. The stock is currently near its 52-week low of $1.32, remaining 21.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $500,000 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.70M↓ | -$10.75M↓ | -$9.98M↓ | -$2.92M↓ | -$2.84M |
| Net Income | -$10.57M↓ | -$9.60M↓ | -$8.90M↓ | -$2.87M↓ | -$2.78M |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate...